Abstract: Background: The development of radiopharmaceuticals containing 225 Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.
INTRODUCTION
Targeted radionuclide therapy using alpha-emitting isotopes combined with disease-specific targeting vectors (antibodies or peptides) has the potential to treat metastatic disease by delivering a source of cytotoxic radiation directly to targeted cells [1] [2] [3] [4] [5] [6] [7] [8] . Given specific targeting, the short range and high cytotoxicity of alpha particles result in the destruction of nearby diseased cells with limited harm to healthy tissues [9] . Due to this potential, the development of alphaemitting radiopharmaceuticals for Targeted Alpha Therapy (TAT) is an active area of academic and commercial research worldwide. Though one alpha-emitting radiopharmaceutical, Xofigo ( 223 RaCl 2 ), is approved for clinical use, the clinical approval of an alpha-emitting isotope combined with a disease-targeting biomolecule has yet to occur and these radiopharmaceuticals remain in the development stages. Several candidate isotopes for TAT are currently under clinical and preclinical evaluation, including 149 Tb, 211 At, 212 Bi, 212 Pb, 213 Bi, 223 Ra, 224 Ra, 227 Th, and 225 Ac. 225 Ac is one promising candidate isotope for TAT due to its 9.9 day half-lifesuitable for targeting with antibodies -and the emission of four alpha particles in its decay chain (it decays to stable 209 Bi via four alpha-and two beta-decays - Fig. 1) . 225 Ac can also be used as a generator of 213 Bi (t 1/2 = 45.6 min), itself a promising TAT isotope.
While several clinical trials have demonstrated the potential of 225 Ac or 213 Bi radiopharmaceuticals to treat advanced *Address correspondence to this author at the Valery Radchenko, Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver BC, Canada, V6T 2A3; Tel/Fax: +1-604-222-7527, +1-604-222-1074; E-mail: vradchenko@triumf.ca cancers [10] [11] [12] [13] , the development of these drugs faces many challenges that have slowed progress, including: 1) the limited supply of 225 Ac -currently only 63 GBq (1.7 Ci) globally annually -which could treat fewer than 1000 patients per year; 2) the need for adequate chemical purification processes required to separate 225 Ac from co-produced stable or unstable isotopes during production; and 3) the need for stable targeting systems with high radiolabeling yields and appropriate pharmacodynamics, the development of which is hindered by a limited understanding of actinium chemistry and complicated by the need to also successfully retain 225 Ac progeny isotopes at the target site despite recoiling daughter nuclei and changing chemistry as the decay chain progresses [14] .
Each section of this review addresses one of these challenges. For each, we summarize the current literature including the current standard methods and any proposed alternatives, and also discuss how performed, planned, and potential activities at TRIUMF attempt to address these challenges facing the development of 225 Ac-radiopharmaceuticals.
PRODUCTION OF 225 AC

Existing 225 Ac Supplies
Current sources of 225 Ac are primarily derived from the build-up of 229 Th through the decay of 233 U stockpiles (see Fig. (1) of the 233 U decay chain). The majority of this 233 U (t 1/2 = 1.6 10 5 y) was produced between 1954 and 1970 via neutron irradiation of 232 Th while being investigated for its use in nuclear weapons and reactors that were never fully deployed [15] . Between 1995 and 2005, 229 Th (t 1/2 = 7340 y)
Leveraging Unique Facilities to Supply 225 Ac Research
Due to the high cost of 225 Ac, 225 Ac-radiopharmaceutical development at TRIUMF currently relies on internal production using the Isotope Separator and Accelerator (ISAC) Facility [26] . Commissioned in 2000, ISAC produces beams of rare isotopes for experiments primarily studying nuclear structure and nuclear astrophysics. Irradiation of uranium or thorium targets with protons at 480 MeV results in the production of a number of isotopes that are extracted into a heterogeneous ion beam. Isotope Separation On-Line (ISOL) mass-separates these isotopes to produce a homogeneous isobaric ion beam [27] . Isolation of mass 225 produces an ion beam containing 225 Ra and 225 Ac that is directed onto an aluminum target in which the isotopes are deposited at a depth of 20 nm (as determined by SRIM [28] ). Etching of the aluminum post-implantation followed by separation of 225 Ra and 225 Ac on a solid phase extraction (DGA) resin provides both a primary 225 Ac fraction for immediate studies, as well as a number of subsequent 225 Ac batches isolated through the decay of 225 Ra. When eluted at the optimal time (every 17.5 days) this generator produces 225 Ac with an activity equal to 44.4% of the 225 Ra activity present at the previous elution 1 . Since 2015, 225 Ac production at ISAC has enabled radiolabeling and preclinical studies at TRIUMF. 1 1 MBq of 225 Ra produces 1/(1-0.444) = 0.80 MBq of 225 Ac from the generator if it is eluted every 17.5 days. Calculations in this publication convert 225 Ra production values to 225 Ac production values using this conversion factor. ISOL methods have also been applied at ISOLDE (CERN, Geneva) to produce 225 Ac for radiopharmaceutical development [29] .
Though ISOL provides isotopically pure 225 Ac sources, yields remain insignificant compared to quantities available from 229 Th generators. At TRIUMF, the maximum measured ISAC beam intensities of 1.3 10 8 ions/s for 225 Ac and 1.6 10 8 ions/s for 225 Ra could theoretically produce up to 370 MBq (10 mCi) of 225 Ac per month 2 , ISAC does not operate as a dedicated medical isotope production facility and 225 Ac production occurs within the overarching context of the laboratory's research program. Total 225 Ac production for 2016 was only 44.4 MBq (1.2 mCi).
In order to better accommodate medical isotope research, the European Organization for Nuclear Research (CERN) has launched the Medical Isotopes Collected from ISOLDE facility (MEDICIS), which plans to produce mass-separated isotope beams from offline targets starting in 2017 and with uranium targets for 225 Ac production available in late 2018 [29, 30] . As a dedicated medical isotope production facility, MEDICIS suggests the capacity to produce up to about 112 MBq (3 mCi) of 225 Ac per month 3 .
The Need for New 225 Ac Production Methods
Estimates of current demand for 225 Ac are less than 185 GBq (5 Ci) per year, however, this is likely significantly tempered by both supply constraints and cost. While predicting future demand is difficult, it can be estimated to grow by about 200 to 400 GBq per year (about 5 to 10 Ci per year) for each 225 Ac-based therapy that is approved for clinical use 4 . Should efforts to develop 213 Bi-radiopharmaceuticals also increase, 225 Ac demands will be even higher.
While facilities like ISAC and MEDICIS can facilitate radiopharmaceutical development by providing access to medical isotopes that are otherwise challenging to obtain, their application will remain limited to medical isotopes in the development stages. Even with potential proposed upgrades to the MEDICIS facility that could enable monthly production of up to 1.7 GBq (45 mCi) of 225 Ac [29] , and potential upgrades to ISAC that could increase yields by a factor of 1000 5 supply enough 225 Ac to support the widespread use of a clinically approved therapy. These facilities should instead be viewed as valuable research enablers whose utility comes from their ability to provide quick access to a range of highpurity medical isotopes so that the feasibility of a given isotope's applications can be explored before having to build dedicated large-scale, isotope-specific production infrastructure.
While harnessing untapped 229 Th supplies has the potential to more significantly impact 225 Ac availability, in 2005 the U.S. Congress ordered the Department of Energy (DOE) to cease extraction of 229 Th from 233 U stockpiles and to instead begin down-blending (dilution with 238 U to a nonweaponizable 233 U concentration) and permanent disposal of the two tonnes of stockpiled 233 U [15] . Petitions to recover 229 Th before 233 U disposition have been denied [20] , and completion of these efforts is scheduled for 2018 [15] . From the high-and intermediate-purity 233 U sources within the inventory [32] 225 Ac production instead of unit cost [19] . While quantities of additional 229 Th-containing 233 U sources may exist in other countries (ex. Russia), quantities -to the best of our knowledge -are unknown.
Without the existence of significant additional 229 Th sources, the use of 225 Ac or 213 Bi in multiple approved therapies will require the development of new 225 Ac production methods. The remainder of this section aims to present a comprehensive list of alternative 225 Ac production options. The potential of each method to meet projected 225 Ac demand and the practical challenges associated with each method will be discussed. Possible production methods proposed in the literature are summarized in Table 1 , while Table 2 summarizes other nuclear reactions capable of producing 225 Ac but that are considered impractical at this time. When not derived from original sources, details of calculations are provided in footnotes.
Potential for 225 Ac Production in Nuclear Reactors
While the majority of medical isotopes today are sourced from nuclear reactors [33] , the potential for reactor-based 225 Ac production is limited. The parent isotope, 225 Ra, can be produced in reactors via the 226 Ra(n, 2n) 225 Ra reaction, however, this reaction requires an intense source of high (>6.4 MeV) neutrons found only near the tail end of a typical breeder reactor neutron energy spectrum. Given that significantly more lower energy neutrons would be present, these irradiations would be dominated by the co-production of 227 Ac, a long-lived (t 1/2 = 21.8 y) and highly toxic actinium isotope, the presence of which in significant quantities may prevent the clinical approval of a pharmaceutical. To the best of our knowledge, this method has not been investigated experimentally or thoroughly modelled. However, rough estimates suggest this method could produce MBq to GBq ( Ci to mCi) amounts of 225 Ac per month per gram of 226 Ra target material at a single reactor facility 6 .
The potential to increase 229 Th stocks using reactors has also been investigated [36, 37] . Results suggest the irradiation of 226 Ra targets at a single reactor could produce 100 MBq (2.7 mCi) of 229 Th per month per gram of 226 Ra target material [36] . Other results have suggested this value may be closer to 59 MBq (1.6 mCi) [37] . While larger specific yields were seen when using 228 
Potential for 225 Ac Production Using Electron Accelerators
The use of the 226 Ra( , n) 225 Ra reaction for 225 Ac production has been experimentally explored [38] and modelled [39] . These works have explored irradiating old radium needles on electron linear accelerators (linacs) found in most modern cancer centres. These linacs typically use electron beams incident on tungsten targets to produce bremsstrahlung x-rays for external beam radiation therapy. Experimental results measured the production of 2. 225 Ac production method may exist, these facilities are used for patient care and, to our knowledge, none are currently equipped with the infrastructure required for safe large-scale isotope pro- 225 Ac production could be increased by up to a factor of 16, although accompanied by an increase in target mass [40] .
Given this low yield, sufficient 225 Ac production via the 226 Ra( , n) 225 Ra reaction would require the use of a facility with significantly higher electron beam current. Though none are dedicated medical isotope production facilities, some such facilities exist for which 225 Ac production values determined by scaling experimental medical linac irradiation results by electron beam current can be found in Table 1 . In addition, TRIUMF's planned Advanced Rare IsotopE Laboratory (ARIEL) facility will use a 35 MeV, 10 mA electron beam to produce intense high-energy x-rays for radioisotope production by photofission [26] . While the ARIEL electron target is intended for operation as an ISOL facility for fundamental research -not a medical isotope production facility -scaling experimental results for 225 Ra production on medical linacs to account for the higher current and different irradiation geometry suggests ARIEL could theoretically produce up to 74 TBq (2000 Ci) of 225 Ac per month from a 1 g 226 Ra target. However, how an isotope production target could survive a 100 kW beam is another unsolved problemcurrent designs for ARIEL ISOL targets only consider 50 kW. Other lower current electron accelerators, such as the existing 50 MeV, 10 A ALTO electron accelerator (Orsay, France) [41] , could theoretically produce up to 56 GBq (1.5 Ci) per month.
Potential for 225 Ac Production using Low Energy Proton Accelerators
The promising use of the 226 Ra(p,2n) 225 Ac reaction to produce 225 Ac on low-energy proton accelerators was first demonstrated in 2005 by Apostolidis et al. [42] . This reaction has a high (710 mb) cross-section peak at 16.8 MeV and could thus be performed on the many low energy cyclotrons already in use worldwide for medical isotope production. An estimated >550 of these cyclotrons have an energy over 16 MeV, some of which operate at up to 500 A [43] . Another advantage of this approach is that it would not coproduce 227 Ac. While the (p, n) reaction is expected to produce some 226 Ac (t 1/2 = 29.4 h), measurements of co-production of 226 Ac have not been reported from experiments found in the literature [42] . A simple FLUKA [44, 45] simulation approximating the Apostolidis et al. experiment suggests an 226 Ac activity at end of bombardment (EOB) equal to 11% the 225 Ac activity. However, unlike with 227 Ac contaminants, the ratio of expected 226 Ac to 225 Ac activity would decrease over time due to the differences in half-lives. The co-production of 225 Ra via the 226 Ra(p,pn) 225 Ra reaction is expected to be negligible at the optimal energies required for direct 225 Ac production [46] . Given the high cross-section, large-scale production of 225 Ac via the (p,2n) reaction would be capable of meeting long-term demand for 225 Ac with only a single production site. Combining available cross-section data [42] Despite its potential, the use of 226 Ra targets poses significant challenges due to the availability of the isotope and safety hazards that complicate the target manufacturing, irradiation, processing, and recycling. Part of the 238 U decay chain, 226 Ra ultimately decays to stable 206 Pb and is typically found in equilibrium with most isotopes in its decay chain. 226 Ra was the first radioactive isotope discovered and was produced in large quantities from the 1920s for use in a number of medical and industrial applications until production stopped in 1960 [48] . Due to its high radiotoxicity, reactivity with water and air, and decay to the noble alphaemitting 222 Rn gas, 226 Ra sources typically contained radium salts encapsulated in platinum [49] . The internal production of helium from the five alpha decays in the 226 Ra chain caused most of these sources to rupture, after which 222 Rn gases are released and 226 Ra salts can leak out. Even when sealed, the high energy gamma rays present from 226 Ra progeny present external radiation hazards, with a dose rate of 8.1 mSv/h at 1 m from a 37 GBq (1 Ci, 1 g) 226 Ra source.
While the use of 226 Ra sources declined after the health effects of radiation exposure became known and safer reactor-based isotopes became available, many 226 Ra sources remained in storage -primarily in hospitals -for decades. The hazards associated with the presence of 226 Ra sources lead many governments to push for the elimination of 226 Ra inventories and in 1996 the International Atomic Energy Agency (IAEA) established guidelines for the disposal of 226 Ra sources in long-term geological repositories [49] . This limits the availability of large 226 Ra quantities, with the IAEA estimating only a few kilograms of 226 Ra exist among 7 Activity produced by a target completely stopping the incident proton beam can be calculated using energy-dependent values for stopping power, S(E), and cross-section, (E), using the following equation: A(t) = , given target density , proton fluence and initial energy E 0 , irradiation time time t, and product isotope decay constant . For this equation, a 226 Ra target density of 5 g/cm 2 was assumed, as well as an irradiation schedule of three 10-day irradiations to get a monthly production value. The integral was performed using fitted data in MATLAB.
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Potential for 225 Ac Production via High-Energy Proton Spallation of Thorium
An alternative 225 Ac production method that avoids the use of 226 Ra targets involves the irradiation of natural thorium targets with protons above 70 MeV. This 232 Th(p, x) 225 Ac reaction produces 225 Ac through a number of reaction pathways, though the total cross-section peaks 40 times lower than for 226 Ra(p, 2n) 225 Ac production (for details on cross-sections, the reader is referred to: [51] ). Thorium metal is the preferred chemical form for post-irradiation processing of the target, and isolation of MBq to GBq ( Ci to mCi) quantities of 225 Ac from irradiated thorium metal has been demonstrated by both American and Russian research groups at Brookhaven National Laboratory (BNL, Brookhaven, NY), Los Alamos National Lab (LANL, Los Alamos, NM), and the Institute for Nuclear Research of the Russian Academy of Sciences (INR) [20, 22, 23, [51] [52] [53] [54] [55] [56] [57] [58] . Unlike 226 Ra (3.7 10 10 Bq/g, or 1 Ci/g), 232 Th (4.1 10 3 Bq/g, 110 nCi/g) is not prohibitively radioactive, poses fewer radiological hazards and is readily available as a target material. Tens of kilograms are known to exist in stockpiles within a number of countries, and more thorium metal is able to be produced in bulk quantities from thorium oxide or thorium nitrate, hundreds of tonnes of which are produced annually worldwide as a by-product of rare-earth mining [50] . This availability means recycling of irradiated 232 Th target material may not be necessary. Another advantage of this method is that facilities already exist with demonstrated ability to perform target fabrication, irradiation, and processing. Examples of accelerator facilities capable of producing large amounts of 225 Ac via proton spallation are listed in Table 1 .
While spallation of naturally occurring 238 U will also produce 225 Ac, 232 Th irradiation is preferred for a number of reasons. The 238 U(p,x) 225 Ac reaction cross-section is 10 times lower (as modelled using FLUKA and GEANT4), and due to the higher density and lower melting point of uranium, thorium targets could more safely handle the higher heat load induced by higher beam currents. The coproduction of fissile 239 Pu and 235 U is also avoided by 232 Th irradiation.
The spallation of thorium produces a number of isotopes other than 225 Ac. While this may provide an opportunity for recovery of other useful isotopes, it also complicates target processing by requiring the separation of dozens of elements. An overview of the different methods for isolating 225 Ac from irradiated thorium is described in Section 3.2.
Concerns exist in the field that the amount of 227 Ac coproduced from thorium spallation will prevent its use as a method for clinical-grade 225 Ac production. An 227 Ac to 225 Ac activity ratio of 0.1-0.2% is typically found in irradiated targets at end of bombardment. However, potential exists for current target processing methods to be modified to produce 225 Ac quantities that are free of 227 Ac by isolation of an radium-actinium generator [59] . Most methods already isolate radium from the irradiated thorium matrix, and if this is done days after EOB, only 228 Ra, 226 Ra , 225 Ra , 224 Ra, and 223 Ra will be present because of the length of their half-lives (t 1/2 = 5.7 y, 1600 y, 14.9 d, 3.6 d, and 11.4 d, respectively). Of these, 228 Ra and 225 Ra beta-decay to actinium isotopes, while the others alpha-decay to radon isotopes. Use of this mixture as a radium-actinium generator will produce 225 225 Ac product with significantly reduced radioactive impurities when compared to the directly produced 225 Ac fraction. While the total 225 Ac yield from this method will be reduced by a factor of about 10, it does not prevent the use of the directly produced, 227 Ac-containing batch of 225 Ac from being used for research or for use in 225 Ac/ 213 Bi generators.
Only a few existing accelerators can produce proton beams with a current and energy sufficient for large-scale 225 Ac production. A list of some of these facilities is given in Table 1 225 Ac production is a more practical limit given the existing target station's size and cooling capacity.
Similarly, practical estimates for production at BNL and LANL are 165 GBq (4.5 Ci) per month [58] .
TRIUMF Perspective on 225 Ac Production
Given the costs and challenges associated with 226 Ra targets, the existing facilities already capable of thorium target spallation, and the large number of successful thorium target irradiations described in the literature, we believe that the development of 225 Ac production via proton spallation of thorium is the fastest way to reliably meet the current global demand for 225 Ac and support the widespread clinical use of any future therapies.
To this end, TRIUMF is working towards the development of routine 225 Ac production via the irradiation of thorium metal targets on its primary beamline (BL1A), which delivers up to 500 MeV, 120 A protons to the currently under-utilized legacy 500 MeV Isotope Production Facility (IPF). Since IPF is located directly before the BL1A beam dump, IPF routinely receives >100 A of beam. Progress so far has included the low-level (2 Ah) irradiation of a prototype thorium oxide target in December 2016. The irradiation of thorium metal targets followed by processing on-site to isolate 370 MBq (10 mCi) of 225 Ac is anticipated for late 2017, followed by 3700 MBq (100 mCi) production in 2018.
RADIOCHEMICAL ISOLATION OF 225 AC
The most established production method is the 229 Th generator, which currently provides the main source of 225 (Fig. 1) is routinely performed at Oak Ridge National Laboratory (ORNL, TN, USA) [16] , Institute for Transuranium Elements (JRC-ITU, Karlsruhe, Germany) [17, 61] , and Leipunskii Institute for Physics and Power Engineering (IPPE, Obninsk, Russia) [62] . At ORNL, 229 Th (5.6 BGq, 150 mCi) stock is divided into several batches and separation occurs every three weeks. A four-step chemical recovery procedure is used, including the combination of anion and cation exchange columns in nitric and hydrochloric media [16] . An anion exchange resin is first used to remove the bulk thorium mass. A 5 60 cm 2 (1.2 L) column filled with MP1 (250±50 mesh) resin, allows the sorption of up to 30 g of thorium in 8 M HNO 3 , while 225 Ac and 225 Ra pass through the column. This process is repeated using a second MP1 column (2 10 cm 2 , 30 mL) in order to separate residual thorium quantities. The fraction containing Ac and Ra is evaporated to dryness and redissolved in 10 M HCl and then loaded onto the next anion exchange (MP1) resin, which allows purification of actinium and radium from iron and uranium micro-impurities. Final separation of 225 Ac from radium is performed on two cation exchange (AG50x4) columns in nitric acid media. Average recovery yield of 225 Ac is 80% over one campaign with radionuclidic purity of over 99%. 3 and mixed with anion exchange resin for storage until the next elution. The Ra and Ac fraction is subject to further purification from residual thorium via solid phase extraction chromatography, using three columns filed with diamyl, amylphosphonate (UTEVA) resin. Separation of Ra from Ac is then performed inoctyl(phenyl)-N,N-diisobutylcarbamoyl-methylphosphine oxide (RE-resin) resin in nitric acid. The reported recovery yield for 225 Ac is higher than 95% with a de-contamination factor from thorium of about 10 2 . The same group also reports alternative separation of 225 Ra and 225 Ac via N,N,N',N"-tetrakis-2-ethylhexyldiglycolamide (DGA) based resin in nitric acid [61] .
At IPPE, separation of 225 Ac and 225 Ra from 229 Th stock (5.6 BGq, 150 mCi) occurs on an anion exchange column in nitric acid followed by Ra/Ac separation on a cation exchange column in diluted nitric acid [18] . The final 225 Ac fraction is additionally purified with a combination of cation and anion exchange columns. A portion of the stock of 229 Th is loaded on an anion exchange column (Dowex 1X8, 0.5 L) in 8 M HNO 3 . As previously described, Ac and Ra pass through the column, while 229 Th is retained. The column is additionally washed with 1 L of 8 M HNO 3 for complete Ac/Ra elution. 229 Th is then stripped with 2.2 L of 0.05 M HNO 3 and converted to 8 M HNO 3 (250-300 mL) for future use. The eluted Ac and Ra fractions are evaporated to dryness and re-dissolved in 0.5 M HNO 3 and passed through a cation exchange column (Dowex 50X8, 6 mL) on which 225 Ac is retained while 225 Ra passes through. The column is further washed with 1.5 M HNO 3 to remove residual 225 Ra isotopes. Actinium is desorbed with 8 M HNO 3 and converted to 10 M HCl for further purification. Finer purification of the 225 Ac solution is performed using anion and cation exchange columns in hydrochloric and nitric acids, respectively. The final actinium product is eluted in 10-12 mL of 8 M HNO 3 the combination of cation and anion exchange chromatography with mixed HNO 3 -methanol solution was also tested [64] . This strategy provides a tandem system for consequent separation of 225 Ac from 229 Th followed by loading of the 225 Ac fraction on a generator for 213 Bi.
225 Ac Isolation from Thorium Targets
As described in Section 2.8, the irradiation of thorium metal with protons above 100 MeV can produce large quantities of 225 Ac. The main challenges associated with the chemical isolation of 225 Ac from these targets are a limited number of facilities capable of handling targets containing large 225 Ac quantities (>10 GBq, or >0.3 Ci) and the challenging chemistry required for separating actinium from multiple grams of thorium and several hundreds of coproduced fission products. As discussed in Section 2.8, another drawback is the co-production of other actinium isotopes, most of which have relatively short half-lives ( 30 hours). One exception is the longest-lived Ac isotope, 227 Ac (t 1/2 = 21.8 y), co-produced at a rate of 0.1-0.2% when compared to 225 Ac activity. While the production of 225 Ac without 227 Ac is possible via the isolation of a 225 Ra/ 225 Ac generator (see Section 2.8), this further complicates the required chemical processing.
Strategies similar to those described in Section 3.1 that use anion exchange columns to retain thorium while eluting Ac and Ra can also be applied to the processing of thorium targets. However, this method requires a large volume of resin to remove the many grams of thorium used as target material -compared to the mg quantities used in 229 Th generators -as well as additional purification steps to remove other spallation products. While several strategies were developed and tested for separation of actinium and radium from thorium [54, 65] , none of these provide actinium with the minimal impurities required for radiolabeling of biomolecules and clinical application.
More recently, two alternative separation methods were developed and tested for isolation of 225 Ac suitable for radiopharmaceutical application. Both methods are practically suitable for masses of thorium of up to 100 grams -larger 232 Th targets will require larger volumes of extraction and chelation agents. The first, described by Aliev et al. [23] , uses a three-step procedure that includes liquid-liquid and solid phase extraction chromatography [23, 57, 66] . First thorium metal target was dissolved in nitric acid with a small portion of HF. Further, two extractions with Di-(2-ethylhexyl)phosphoric acid (HDEHP) were performed, where the bulk thorium mass was extracted into in the organic phase while actinium, radium and most spallation products were retained in aqueous phase. Following phase separation, the aqueous phase is passed through N,N,N',N"-tetrakis-2-ethylhexyldiglycolamide (DGA) column for separation of actinium and lathanides from fission products and radium in nitric acid media. The Ac and lanthanide fraction is then processed using TRU resin in 3 M HNO 3 . Reported recovery yields for actinium are higher than 85% and the process was adopted to a hot cell environment for remote manipulation [23] . A modified strategy has also been applied to co-extract 223 Ra along with 225 Ac [67] .
The second method was the result of an multiinstitutional collaboration within the US DOE that included Los Alamos, Oak Ridge and Brookhaven National Laboratories [22, 68, 69] . This two-step procedure first removes the bulk thorium mass by chelating thorium and spallation products in 1 M oxalic acid at pH 2. At these conditions, all cations with charge 4+ and higher form negatively charged complexes, while cations with lower charge form positively charged complexes. Therefore, positively charged actinium and radium complexes are retained on the cation exchange resin while the bulk mass of thorium and majority of the fission products pass through the column without absorption. A similar strategy had also been previously used for 229 Th/ 225 Ac generators [63] . Ac and Ra are then eluted in 6 M HNO 3 and directly loaded onto a solid phase extraction chromatography column (N,N,N',N"-tetrakis-2-ethylhexyldiglycolamide (DGA branched). At loading conditions, 2+ charged cations (e.g. Ra and Ba) pass through the column without sorption and actinium and lanthanides are retained. Actinium can be separated from lanthanides by specifically eluting with 10 M HNO 3 from the DGA column, while lanthanides are retained under such conditions. Reported recovery yield of actinium is higher than 98% with high radionuclidic and radiochemical purity suitable for radiolabeling or generator application.
This strategy has been further improved by additional steps for the co-extraction of other valuable medical radionuclides -including 225, 224, 223 Ra, 230 Pa, 103 Ru and 111 Agwithout disturbing the actinium purification process [70] .
225 Ac Isolation from 226 Ra Targets
Irradiation of radium with low energy protons and photons also results in 225 Ac production (see Sections 2.5 and 2.6). From a radiochemical separation standpoint, 225 Ac needs to be isolated from macroscopic amounts of radium isotopes and their daughters. Previously published work suggests the use of a two-step procedure for 225 Ac purification [42] . Irradiated 226 Ra targets are dissolved in 0.01 M HCl, followed by purification of Ac from the bulk Ra mass (plus small Po and Pb quantities) by sorption of 225 Ac on di(2-ethylhexyl) orthophosphoric acid (HDEHP) resin (LN-resin) in 0.01 M HCl. The column is washed with 0.1 M HCl and actinium was eluted with 2 M HCl. The second purification step uses 4,4'(5')-di-t-butylcyclohexano 18-crown-6 (crown ether) resin (Sr-resin) for removal of residual amounts of radium and its daughters. The actinium fraction was passed through the Sr-resin column in 2 M HCl. No radiochemical yields or specific values for radiochemical purities have been reported for this method reported, though radiochemical purity is stated to be similar to 225 Ac derived from 229 Th generators.
Status at TRIUMF
At TRIUMF, several production routes for 225 Ac are currently in use and under consideration. The collection of 225 Ra and 225 Ac ion beams at ISAC (see Section 2.2), is followed by a radiochemical separation consisting simply of one DGA column in nitric acid. However, chemical purity of 225 Ac is still under evaluation due to the possible stable impurities originating from the implantation target. As mentioned in Section 2.9, 225 Ac production via irradiation of sealed tho-rium metal targets is also planned at TRIUMF's 500 MeV Isotope Production Facility, located on beamline 1A. While isolation of actinium and radium isotopes can be performed with one of the previously described strategies, any potential future full utilization of the high proton beam energy will require irradiation of large targets (>100 g). Therefore, alternative separation strategies are under evaluation. The upcoming ARIEL facility [26, 71] will also provide additional opportunity for irradiation of thorium targets with protons (480 MeV, 10-100 A) as well irradiation of radium targets with photons. Design of radium targets and radiochemical separation of actinium from bulk radium are currently under consideration by our Life Sciences group.
TARGETING DESEASE WITH 225 Ac
Chemistry of 225 Ac and Radiolabeling Challenges
The lack of any stable actinium isotopes has restrained the advancement of actinium chemistry, and as a consequence the chemistry of Ac(III) is virtually unknown [72, 73] . Only very recently have some studies begun to elucidate the fundamental coordination chemistry of this highly radioactive element [74, 75] . Actinium isotopes are typically +3 ions with a documented ionic radius of 112 pm (CN 6) [76] ; its large size is likely suited to large polydentate chelators of high denticities, since most commonly used chelates for Ac(III) range between 8-12 coordinate [72] . Actinium is similar to other actinides and rare earth elements, and can undergo hydrolysis in solution in the absence of a chelating agent to form [Ac(OH) 3 x ] x-; the sub-picomolar concentrations of 225 Ac will cause the hydroxide species in turn to form radiocolloids that bind to surfaces such as reaction vessels [77] .
The emission of multiple alpha-particles in the 225 Ac decay chain (Fig. 1) makes 225 Ac a particular effective isotope to kill cancer cells, yet also makes the directed delivery of the nuclide and its decay daughters a challenge. Due to the conservation of momentum, the emission of an energetic alpha particle (energies shown in Fig. (1) ) imparts a recoil energy to the daughter nucleus often >100 keV, 1000 times larger than the binding energy for any chemical bond [14] . This results in release of the daughter nuclide from the original delivery vector (Fig. 2) . The subsequent redistribution of the alpha-emitting daughter nuclides in vivo can cause substantial harm to untargeted healthy tissues and reduce the therapeutic effect. Consequently, renal toxicity induced by 213 Bi is considered to be a major constraint to the application of 225 Ac in a large number of clinical trials [78] . There are three main strategies for limiting the toxicity of recoil daughters in the literature: fast uptake and internalization of the alpha emitters in the target tissue, encapsulation of the nuclide in a nanoparticle, or local administration of radioactivity directly into the target site via injection [14] . Herein, a literature review of the first two strategies is included.
Chelating Agents for 225 Ac(III)
The discovery of a chelating agent that binds Ac(III) with sufficient stability and that also controls the release of its daughter nuclides remains a challenge. Moreover, limited global availability of 225 Ac and the absence of a stable surrogate nuclide has limited the study of this isotope to a handful of institutions around the world that have secured a reliable 225 Ac supply. The majority of initial 225 Ac chelation studies have focused on screening a variety of commercially available polydentate macrocyclic or acyclic ligands for their ability to bind 225 Ac and form stable complexes in vitro or in vivo. Despite the unique coordination preferences of the large +3 actinide, very few studies investigating new ligands specifically designed to coordinate Ac(III) can be found throughout the literature. A brief summary of ligands tested with 225 Ac can be found in Table 3 . 225 Ac-complexes were assessed by injecting 92 kBq (2.5 Ci) of each complex, and compared to the 225 Ac-acetate biodistribution as a control. Since uncomplexed 225 Ac accumulates predominantly in the liver with small amounts in the bone, kidney, and heart, high liver uptake of an 225 Ac-chelate indicates an unstable complex in vivo. CHX-A"-DTPA and PEPA reduced liver uptake of the 225 Ac-complex by more than 5.5 times compared to 225 Ac-acetate, and although their data suggests 225 Ac-CHX-A"-DTPA to be the most effective tested chelator complex with regard to its in vivo stability, improvements can still be made to further reduce non-target tissue accumulation [77] . As such, CHX-A"-DTPA provides inadequate chelation of (2) . Depiction of the recoil effect associated with -decay of 225 Ac. Daughter isotope 221 Fr is released from the chelating agent due to the 100 keV recoil energy associated with the alpha emission of 225 Ac. 221 Fr and its decay daughters are consequently free to migrate within in the body. Ac(III). Another important finding of the initial in vivo study was that the maximum tolerated dose of 225 Ac-CHX-A"-DTPA was less than 185 kBq (5 Ci), since at doses of 185 kBq (5 Ci) or higher, severe tissue damage was observed as early as 1 hr post-injection (p.i.), which ultimately lead to death causing 100% mortality by day 8 p.i. [77] . N,N',N",N"',N"",N" "'-hexaacetic acid, N 6 O 6 ), and compared its in vivo stability to 225 Ac labeled EDTA, CHX-A"-DTPA, DOTA, and PEPA [80] . 225 Ac-HEHA demonstrated the highest complex stability evidenced by the low uptake of the complex in all tissues; essentially all radioactivity was excreted within 1 hour. Despite this perceived in vivo stability, the authors suggested the predicted -3 charge at physiological pH of the 225 Ac-HEHA complex may be mediating the fast excretion of the complex, giving it the appearance of stability since the radiometal ion doesn't have time to dissociate within the time frame of excretion [80] . Given these initial promising results, efforts towards the preparation of a bifunctional HEHA analogue were undertaken [81] . A C-functionalized isothiocyanate HEHA derivative was successfully prepared and conjugated to three monoclonal antibodies (mAbs): BL-3, T101, and CC49. One-step labeling of 225 Ac to HEHA-mAb incubated for 30 min at 37 °C, pH 7.0 produced moderate to high RCYs of 60-85% with specific activities of 7.4-14.8 MBq/mg (200-400 Ci/mg) (for ligand:mAb ratios > 1.0); these bioconjugates were sufficient for animal therapy studies. In vitro serum stability revealed the 225 Ac-HEHA-BL-3 mAb conjugate to be only 50% stable in serum after 24 h, suggesting that the HEHA system may very well not be a suitable chelator for sequestering 225 Ac [81] . [79] . Of the six ligands tested, only DOTA and DOTMP showed any complexation of 225 Ac after 2 h at 37°C with RCYs of >99 and 78%, respectively. Subsequent in vitro stability assays in serum suggested that the 225 Ac-DOTA complex was robust, remaining >90% intact after 10 days, while the 225 Ac-DOTMP complex rapidly dissociated.
Early studies by Davis
The initial promising in vitro stability of 225 Ac-DOTA motivated the authors to prepare conjugates of DOTA with antibodies HuM195 (anti-CD33), mJ591 and huJ591 (anti-PSMA), B4 (anti-CD19), and 3F8 (anti-GD2). The elevated temperatures required to achieve adequate labeling yield of Ac-DOTA were not amenable to antibody conjugates since such reaction conditions would denature proteins and result in loss of function. Consequently, a two-step labeling process was employed which required 225 Ac radiolabeling of the bifunctional DOTA-NCS ligand first, followed by mAb conjugation (pH 8.7, 37 °C for 52 min). Despite low overall radiochemical yields of only 9.8 ± 4.5%, reasonable specific activity (4.1 ± 2.6 GBq/g, or 0.11 ± 0.07 Ci/g) was achieved which would allow for preclinical therapeutic studies. Low yields were attributed to the first 225 Ac labeling step of DOTA-NCS which required heating and, consequently, degradation of the isothiocyanate linker resulting in poor mAb conjugation in the following step.
Attempts to increase the 2-step labeling yields of 225 Ac-DOTA-mAb conjugates via the modification of a more robust DOTA-linker chelate system have yielded some improvements [82] . Antczak et al. established a 2-step labeling protocol for thiol-based DOTA-linkers which provided a marked improvement compared to the DOTA-NCS 2-step method, with chelation yields of 95-99% and labeling yield up to 40%. In the same study, the authors incorporated an enzymatically cleavable linker which could minimize the toxicity associated with long-circulating mAbs to normal tissues by allowing the release of a small molecular weight radiometal-chelate complex from the mAb to promote fast clearance of the therapeutic nuclide. However, constructs resulted in high accumulation of 225 Ac in the liver in small animal models, indicative of 225 Ac release from the chelate [82] .
Perhaps the most noteworthy improvement to 225 Ac radiolabeling to date was presented by Maguire et al. [83] , which offered for the first time an efficient 1-step radiolabeling procedure for 225 Ac-DOTA-antibody constructs. Typical radiolabeling proceeded in 2 M tetramethyl ammonium acetate buffer (pH 7.5) with the addition of L-ascorbic acid as radioprotectant to the addition of DOTA-antibody construct and 225 Ac 3+ with a typical final reaction pH of 5.8. Heating to 37°C for 2 hours allowed a 10-fold increase in radiochemical yield (80%) compared to previous 2-step methods (6-12%), and resulted in the preparation of bioconjugates with up to 30-fold higher specific activities (120 GBq/g compared to 3.7-14.8 GBq/g) [83] . The highest specific activity achieved was equivalent to 1 actinium for every 25 antibodies. These results will likely have great implications in preclinical and clinical uses of 225 Ac labeled antibodies, since the ease of synthesis can more easily be translated in a clinical setting and the significant reduction of 225 Ac losses during labeling can save the cost of this rare and valuable isotope.
Bioconjugates for 225 Ac Labelling
Despite often requiring elevated temperatures and extended reaction times, promising stability in serum and efficient labeling of 225 Ac-DOTA complexes has cemented the commercial chelator and its bifunctional analogues as the most exploited chelator for 225 Ac thus far. With the relatively limited scope of chelates tested with 225 Ac to date (see Table  3 ), and very few examples of specifically tailored Acchelates in the literature, it seems apparent there is much room for improvement in the field of Ac-chelation, particularly as more powerful spectroscopic and computational techniques evolve that will continue to help elucidate the In vitro human stability, 37
C remained 90% intact after 10 days. [74] . Nonetheless, 225 Ac labeled DOTA-small molecule [10] , peptide [84] [85] [86] , and antibody [78, 87, 88] conjugates have been tested in a variety of in vitro and in vivo preclinical studies, and a select few have seen clinical successes. Specifically, the 225 Ac-labeled humanized anti-CD33 (HuM195) mAb is in clinical trials for the treatment of patients with advanced myeloma [89] . Most recently a brief communication by Kratochwil et al. [10] reported remarkable treatment success in two patients with metastasized castration-resistant rostate cancer (mCRPC) who had extensive pretreatments and showed resistance to other therapies including beta-emitting radiopharmaceuticals. The small molecule 225 Ac-PSMA-617 (Fig. 3) was administered bi-monthly at doses of 100 kBq/kg (2.7 Ci/kg); patient 2 saw complete remission after 3 treatment cycles. In vivo decomplexation indicated by high liver uptake [77] 
225 Ac Labelled Nanoparticles
To circumvent the inevitable loss of 225 Ac daughters after alpha decay from an actinium-chelate complex, researchers have sought to encapsulate the highly potent alpha-emitter into a nanoparticle structure. It is hypothesized that the 225 Ac 3+ ion and its decay daughters can be retained within the cavity of the nanoparticle structure, while the alpha particles are released and able to deposit their therapeutic dose at the intended target site. However, the use of nanoparticles as a platform to affix radionuclides or other biomolecular targeting vectors comes with several limitations. The biodistribution of nanoparticles is dominated by their large size and ability to take advantage of the enhanced permeability and retention (EPR) effect of cancer cells, where "leaky" vessels of poorly vascularized tumours allow for the uptake and retention of large macromolecules [72] . Moreover, the relatively large particles are often primarily excreted through the hepatic pathway which can cause unwanted high liver uptake. The accumulation of a highly toxic alpha-emitter in the liver may cause damage to the organ. Much of the available literature describing 225 Aclabeled nanoparticles provides in vitro data only [90] [91] [92] [93] [94] [95] . Nonetheless, a brief overview of some strategies to prepare 225 Ac radiolabeled nanoparticles is found below.
Work by Matson et al. [94] investigated the encapsulation of 225 Ac 3+ ions in single-walled carbon nanotubes (SWNTs) by co-encapsulation of Gd 3+ in an ion cluster. Although the Gd 3+ ions remained inside the SWNTs, continual leakage of the 225 Ac 3+ ions was seen when challenged with serum. McLaughlin et al. [90] employed a multilayered nanoparticle structure which can contain the recoiling daughters of the in vivo alpha generator at the centre cavity, while coupling the outer layer to antibodies and without preventing the release of emitted alpha-particles. The shells included a radiation resistant lanthanide phosphate crystal doped with 225 Ac and layered with a magnetic GdPO 4 layer, plus a gold outer shell for the attachment of targeting vectors. Polymer vesicles (polymersomes) composed of poly(butadiene-bethylene oxide) have also been used to encapsulate 225 Ac [92] . Preliminary in vitro studies in cells showed that smaller particles were absorbed by the cells and gathered around the cell nucleus. However, experiments and simulation indicated that larger polymerases are needed to attain satisfactory retention of recoiling daughters [92] . PEGylated liposomes loaded with 225 Ac and labeled with mouse antihuman PSMA J951 antibody or with the A10 PSMA aptamer were tested in vitro for their targeting, internalization, and cytotoxicity on a prostate cancer cell line [91, 95] . These studies demonstrated anti-PSMA targeted liposome loaded with 225 Ac can selectively bind, become internalized, and kill PSMA-expressing cells. Similarly, a 225 Ac-loaded lipid-based nanocarrier was labeled with a PSMA targeting antibody or small molecule urea-based agent, and the targeting selectivity and cytotoxicity were compared to the radiolabeled antibody on its own [95] . It was found that the loaded lipid vesicles improved the killing efficacy 3-fold compared to the same levels of activity per cell when delivered by the PSMA-targeting antibody.
Assessing the Biodistribution of the 225 Ac Decay Chain
While this discussion so far has been limited to the biodistribution of 225 Ac itself, assessment of the biodistribution of each alpha-emission in the decay chain is necessary when evaluating the performance of 225 Ac-radiopharmaceuticals. As previously mentioned in Section 4.1, the retention or redistribution of 221 Fr, 217 At, and 213 Bi at the target site impacts the efficacy and toxicity of the radiopharmaceutical. While the half-life of 217 At is short enough that its biodistribution can be assumed to be effectively identical to 221 Fr, the short 221 Fr half-life makes accurately determining its biodistribution -and also independently determining the biodistribution of its 213 Bi granddaughter -a challenge using conventional ex vivo counting methods. Speedy harvesting and counting of organs is essential, since while successive measurements of the same ex vivo tissue samples over time can be used to estimate the amount of 221 Fr or 213 Bi present at the time of sacrifice, the uncertainty in these estimates increases the longer after sacrifice the first measurements are made [14] .
Imaging-based methods can also be used to assess the biodistribution of the radionuclides in vivo, and quantitative SPECT imaging of 225 Ac progeny isotopes has been demonstrated on small-animal SPECT/CT systems for 213 Bi alone [96] , and for both 221 Fr and 213 Bi simultaneously, via their 218 keV and 440 keV gamma lines, respectively [97] . Unfortunately, quantitative imaging of the high energy 213 Bi photopeak (440 keV) requires the use of a high energy collimator not available on most imaging systems. However, qualitative SPECT imaging of 213 Bi has been performed clinically, as has qualitative 221 Fr SPECT in preclinical settings [11, 12, 90, 98, 99] . The use of Cerenkov imaging has also been demonstrated in vivo for the 225 Ac decay chain [86] , though this imaging modality is incapable of quantitative biodistribution measurements and cannot distinguish between individual 225 Ac decay chain components.
While quantitative SPECT imaging of 221 Fr and 213 Bi with sub-millimeter spatial resolution has the potential to assess the retention of 225 Ac progeny within the tumour and determine uptake within whole organs [97] , the short range (<100 m) of alpha particles mean that information regarding the sub-organ biodistribution -a level of detail not provided by current in vivo imaging modalities -is necessary for alpha-particle dosimetry [100, 101] . While ex vivo imaging using alpha-cameras can determine 225 Ac biodistributions with spatial resolutions sufficient for dosimetry [102] [103] [104] [105] [106] , alpha particle dosimetry itself faces additional challenges that currently limit the translation of preclinical dosimetric data to biological outcomes in the clinic [100, 101] , a discussion of which is beyond the scope of this review.
Progress at TRIUMF
By leveraging our existing infrastructure TRIUMF has established 37 MBq (1 mCi) annual production of 225 Ac via our ISOL facility (Section 2.2). This 225 Ac has enabled TRI-UMF to conduct a variety of preclinical radiolabeling, complex stability, and imaging studies [97] . In particular, the apparent lack of chelating agents available to complex 225 Ac under conditions commensurate for "kit" type preparation of radiopharmaceuticals has motivated our researchers to search for alternate ligands which can quantitatively sequester the radioactive metal under mild, room temperature conditions with low ligand concentrations while forming thermodynamically stable and kinetically inert radiometal-chelate complexes. To this end, we are currently screening a wide 225 Ac radiolabeling efficiencies and high in vitro stability will be conjugated to selected antibody or peptide targeting vectors, and small animal in vivo studies can be conducted.
CONCLUSION
With some recent and remarkable clinical results in the treatment of late-stage cancers using beta-and alphaemitting radiopharmaceuticals, the community has experienced a surge in interest in certain therapeutic isotopes. Supply challenges, especially for isotopes such as 225 Ac, have limited the development of existing and emerging targeted radiotherapeutics, and pose a significant challenge in the discovery of new agents. That said, there exists a substantial amount of untapped production potential across a number of facilities.
Discussed within are the different 225 Ac production routes which span the spectrum of neutron (reactor), electron (gamma) and proton-induced reactions. At this time, the most promising short-term approach to greater availability of 225 Ac would be to irradiate thorium metal with high energy (>70 MeV) protons. By enable existing facilities with access to protons in this energy range to produce 225 Ac, it will allow for a focus on addressing unanswered questions on a specific activity, radiochemical and/or radionuclidic purity. There exists the possibility of exploiting the co-production of 225 Ra to assemble and distribute 225 Ra/ 225 Ac generators -a route that could help reduce the amount of 227 Ac in the 225 Ac used for radiopharmaceutical preparation. 225 Ac produced during the irradiation itself could be used for manufacturing 225 Ac/ 213 Bi generator. Beyond this, safety challenges will continue in the handling and processing of irradiated Th targets given their extensive radionuclide content, which can be mitigated by leveraging the experience and repurposing equipment from facilities designed to handle large quantities of radioactive material from reactor fuel and waste processing.
Given the widespread availability of lower energy (16) (17) (18) (19) (20) (21) (22) (23) (24) MeV) medical cyclotrons, there also exists the tantalizing possibility of large-scale, decentralized production across the fleet of the hundreds of medical cyclotrons in operation across the globe today. The key challenge, in this case, would be more on the procurement of sufficient quantities of 226 Ra, not to mention the safety implications of a failed irradiation in a hospital-based setting.
Adequate radiopharmaceuticals will also require the optimization of chelate design, with several advances having been recently reported. Enhanced supply will allow for the study and identification of compounds with the most suited pharmacokinetic profiles for therapy with minimized bystander organ dose or side effects. With clinical interest increasing, the most efficient way forward would be to enable increased production quantities by building or enabling existing facilities to produce isotopes such as 225 Ac at the bulkscale. By using these facilities to supply sufficient and routine quantities of 225 Ac to advance existing clinical trials for compounds in clinical development -and should the early results seen to date represent results anticipated from a larger patient pool -there will undoubtedly be an increase in demand for more alpha-therapeutics toward more indications.
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